DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
DBV Technologies (Nasdaq: DBVT) announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, 2025 at 2:00 p.m. ET in Boston, Massachusetts.
A live webcast will be available via the company’s Events page and an archived replay will be accessible for 90 days after the event. The presentation offers investors a direct opportunity to hear management remarks and strategic commentary.
DBV Technologies (Nasdaq: DBVT) ha annunciato che Daniel Tassé, Amministratore Delegato, parteciperà a una chiacchierata informale al Guggenheim 2ª Annual Healthcare Innovation Conference il martedì 11 novembre 2025 alle ore 14:00 ET a Boston, Massachusetts.
Una trasmissione in diretta sarà disponibile tramite la pagina Eventi dell’azienda e una replica archiviata sarà accessibile per 90 giorni dopo l’evento. La presentazione offre agli investitori una opportunità diretta di ascoltare le osservazioni della direzione e i commenti strategici.
DBV Technologies (Nasdaq: DBVT) anunció que Daniel Tassé, Director Ejecutivo participará en una charla informal junto al fuego en la Guggenheim 2nd Annual Healthcare Innovation Conference el martes 11 de noviembre de 2025 a las 2:00 p. m. hora del Este en Boston, Massachusetts.
Una transmisión en vivo estará disponible a través de la página de Eventos de la empresa y una reproducción archivada estará accesible durante 90 días después del evento. La presentación ofrece a los inversores una oportunidad directa de escuchar las declaraciones de la dirección y los comentarios estratégicos.
DBV Technologies(나스닥: DBVT)가 Daniel Tassé 최고경영자가 구겐하임 2nd Annual Healthcare Innovation Conference에서 파이어사이드 채팅으로 참여할 예정이라고 발표했다. 일정은 2025년 11월 11일 화요일 동부 표준시 14:00 보스턴, 매사추세츠에서 열립니다.
라이브 생중계는 회사의 Events 페이지를 통해 이용 가능하며 이벤트 종료 후 90일 동안 아카이브 재생을 이용할 수 있습니다. 발표는 투자자들에게 경영진의 발언과 전략적 해설을 직접 들을 수 있는 기회를 제공합니다.
DBV Technologies (Nasdaq: DBVT) a annoncé que Daniel Tassé, Directeur général participera à un fireside chat lors de la Guggenheim 2nd Annual Healthcare Innovation Conference le mardi 11 novembre 2025 à 14h00 HNE à Boston, Massachusetts.
Un webcast en direct sera disponible via la page Événements de l'entreprise et une rediffusion archivée sera accessible pendant 90 jours après l'événement. La présentation offre aux investisseurs une opportunité directe d'entendre les remarques de la direction et les commentaires stratégiques.
DBV Technologies (Nasdaq: DBVT) gab bekannt, dass Daniel Tassé, Chief Executive Officer an einem Fireside-Chat bei der Guggenheim 2nd Annual Healthcare Innovation Conference am Dienstag, dem 11. November 2025 um 14:00 Uhr ET in Boston, Massachusetts teilnehmen wird.
Ein Live-Webcast wird über die Veranstaltungsseite des Unternehmens verfügbar sein und eine archivierte Wiedergabe wird 90 Tage nach der Veranstaltung zugänglich sein. Die Präsentation bietet Investoren eine direkte Möglichkeit, die Bemerkungen des Managements und die strategischen Kommentare zu hören.
DBV Technologies (ناسداك: DBVT) أعلنت أن دانيال تاسيه، الرئيس التنفيذي سيشارك في جلسة fireside chat في المؤتمر Guggenheim للابتكار في الرعاية الصحية، الدورة الثانية يوم الثلاثاء 11 نوفمبر 2025 الساعة 2:00 مساءً بتوقيت شرق الولايات المتحدة في بوسطن، ماساتشوستس.
سيكون البث المباشر متاحاً عبر صفحة الفعاليات للشركة وسيكون بإمكان الوصول إلى إعادة تشغيل أرشيفية لمدة 90 يوماً بعد الحدث. تقدم الجلسة للمستثمرين فرصة مباشرة لسماع ملاحظات الإدارة والتعليقات الاستراتيجية.
- None.
- None.
Châtillon, France, November 4, 2025
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, at 2:00 p.m. ET in Boston, Massachusetts.
A live webcast of the fireside chat be accessed here and will also be available on the Events section of the Company’s Investors website: https://dbv-technologies.com/investor-overview/events/, with an archived replay accessible for 90 days following the event.
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
VIASKIN is a registered trademark of DBV Technologies.
Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com
Attachment
FAQ
When will DBV Technologies (DBVT) present at the Guggenheim Healthcare Innovation Conference?
How can investors watch the DBVT fireside chat on November 11, 2025?
Will the DBVT Guggenheim conference replay be available after the live event?
What ticker should investors use to follow DBV Technologies before and after the conference?
What topics will DBVT CEO likely cover during the November 11, 2025 fireside chat?
Where is the Guggenheim 2nd Annual Healthcare Innovation Conference taking place for DBVT’s presentation?
